^
Association details:
| Biomarker: | TP53 mutation + ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Excerpt:
At the mutation level, TP53 was the most frequently mutated gene and was only observed in patients with the shortest progression-free survival (PFS)...Our data show the presence of TP53 mutation as a strong prognostic indication of poor clinical response in ALK+ NSCLC.
DOI:
10.1158/1535-7163.MCT-19-0105
